Samuel Agresta

Samuel Agresta is an experienced medical executive currently serving as the Chief Medical Officer at OnKure Therapeutics since February 2024. Prior roles include Chief Medical Officer at Infinity Pharmaceuticals from August 2018 to September 2019 and Vice President of Clinical Development at Agios Pharmaceuticals from December 2011 to August 2018. Additional experience encompasses positions as Senior Medical Director at Merrimack Pharmaceuticals, Medical Director at Genentech, and Associate Medical Director at Moffitt Cancer Center. Samuel Agresta earned an MD in Medicine from Tulane University and Tulane University School of Medicine between 1994 and 1999, and a degree in History from Georgetown University from 1990 to 1994.